• info@betterlife-technologies.com
  • + 202 22576731
  • 09:00 – 17:00 Saturday to Thursday

RenalGuard

RenalGuard

RenalGuard Solutions, Inc. is a medical device company focused on innovative technologies for the cardiac and vascular markets. The company’s lead product is designed to protect patients from procedure-induced acute kidney injury (AKI) which may result from cardiac surgery and heart cath procedures, and may also be present in ICU patients. Our goal is to help improve morbidity and mortality rates in these patients, preserve quality of life, and reduce healthcare costs through the use of our technology.

Products

Acute Kidney Injury (AKI) can occur during common hospital procedures including open heart surgery, minimally invasive heart cath procedures, and with ICU patients. RenalGuard is the only system offering a complete solution to patients at risk of AKI. The device is CE-marked for sale in Europe and a variety of countries throughout the world, and is under investigation in the U.S.

RenalGuard

RenalGuard Therapy is designed to reduce the toxic effects that contrast media can have on the kidneys, which may lead to a reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients. RenalGuard Therapy® is based on existing published literature, including the PRINCE study1, which support the theory that creating and maintaining a high urine output through the kidneys allows the body to rapidly eliminate contrast, reducing its toxic effects.